Intercellular Signaling Peptides and Proteins

Name
Intercellular Signaling Peptides and Proteins
Accession Number
DBCAT000080
Description

Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal.

Drugs
DrugDrug Description
Denileukin diftitoxA recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor.
Peginterferon alfa-2aA modified form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.
Interferon alfa-n1A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
Darbepoetin alfaA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
ErythropoietinA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
Interferon alfa-n3A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
PegfilgrastimA recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy.
SargramostimA modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant.
Peginterferon alfa-2bA purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers.
AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease.
Interferon gamma-1bA form of recombinant human interferon used to treat infections associated with chronic granulomatous disease and to slow the progression of severe malignant osteopetrosis.
OprelvekinA form of recombinant interleukin-11 used to stimulate production of megakaryocytes and platelets in patients with or at risk of thrombocytopenia after chemotherapy.
PaliferminA form of recombinant human keratinocyte growth factor used to prevent and treat oral mucositis following radiation or chemotherapy.
AldesleukinA recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.
Interferon beta-1aA form of recombinant human interferon used to slow disease progression and reduce the frequency of clinical symptoms in patients who have relapsing multiple sclerosis.
Interferon beta-1bA form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms.
Interferon alfacon-1A recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections.
BecaplerminA recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area.
MecaserminA recombinant insulin-like growth factor-1 used for the long-term treatment of growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion due to the development of neutralizing antibodies to GH.
AbaloparatideA parathyroid hormone-related protein (PTHrP) analog used for the treatment of osteoporosis in postmenopausal women with a high risk of fracture.
LeptinInvestigated for use/treatment in lipodystrophy and obesity.
Interferon alfaInvestigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma.
Cintredekin BesudotoxInvestigated for use/treatment in brain cancer.
RomiplostimA fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
Ciliary neurotrophic factorInvestigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).
Albinterferon Alfa-2BInvestigated for use/treatment in hepatitis (viral, C).
Fibroblast growth factor-1Investigated for use/treatment in coronary artery disease and peripheral vascular disease.
IRX-2Investigated for use/treatment in cancer/tumors (unspecified), head and neck cancer, and solid tumors.
Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
CTCE-0214Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases.
IRL-1620Investigated for use/treatment in cancer/tumors (unspecified).
IcatibantA bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).
TraferminInvestigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.
EndostatinInvestigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
RepiferminInvestigated for use/treatment in bone marrow transplant, ulcers, and inflammatory bowel disease.
VelaferminInvestigated for use/treatment in adverse effects (chemotherapy).
ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
LabradimilInvestigated for use/treatment in brain cancer and pediatric indications.
EmfilerminInvestigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility.
MetreleptinA leptin analogue used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
AncestimA human stem cell factor used in combination with filgrastim during autologous peripheral blood progenitor cell (PBPC) transplantation to increase PBPC mobilization for improved collection.
Methoxy polyethylene glycol-epoetin betaA synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease.
Peginterferon beta-1aAn interferon beta used to treat relapsing forms of multiple sclerosis.
Epoetin deltaEpoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Eptotermin AlfaA bone morphogenetic protein that is widely expressed during EMBRYONIC DEVELOPMENT. It is both a potent osteogenic factor and a specific regulator of nephrogenesis. Eptotermin Alfa is an ingredient in...
Dibotermin alfaindicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation [FDA Label]. indicated for single-level...
AvoterminJuvista has been investigated for the treatment, prevention, and basic science of Scars, Keloid, and Cicatrix.
TAK-448TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.
Interleukin-7Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
NagrestipenNagrestipen has been used in trials studying the treatment of CANCER, Neoplasm, Metastasis, Radiation Oncology, and Neoplasm Metastasis.
BradykininBradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.
BinetrakinBinetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others.
DulanerminDulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer.
MuplestimMuplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in...
MolgramostimMolgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.
SpriferminSprifermin has been used in trials studying the treatment of Osteoarthritis, Knee and Cartilage Injury of Knee.
Nerve Growth FactorNerve Growth Factor has been used in trials studying the prevention and treatment of Mental Handicap, Alzheimer's Disease, Traumatic Brain Injury, Cerebral Palsy Children, and Delayed Speech Development, among others.
Endothelin-1Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).
BalugrastimBalugrastim has been used in trials studying the treatment of Solid Tumors.
Interleukin-10Interleukin-10 has been used in trials studying the prevention and treatment of Vasculitis, Pancreatitis, Bile Duct Diseases, Pancreatic Diseases, and Gallbladder Diseases, among others.
LenograstimThe drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of...
LipegfilgrastimA medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy.
Interleukin-1 alpha, human recombinantNot Annotated
Basic Fibroblast Growth FactorBasic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications.
NepiderminNot Annotated
Insulin-like growth factor IIThe insulin-like growth factor II is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. This factor presents effects related to growth...
RegramostimInvestigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
Sar9, Met (O2)11-Substance PInvestigated for use/treatment in acute respiratory distress syndrome (ARDS) and viral infection.
Peginterferon lambda-1aPeginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C).
Human interleukin-2Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
Human interferon betaA polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS).
Recombinant CD40-ligandRecombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
LeridistimLeridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).
Interferon alfa-2cInterferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).
ALT-801ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
Tucotuzumab celmoleukinTucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous...
Lorukafusp alfaLorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
EndostarEndostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
BempegaldesleukinBempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib...
PegilodecakinPegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).
PegbelferminPegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).
Edodekin alfaEdodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or...
Drugs & Drug Targets
DrugTargetType
Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
Denileukin diftitoxCytokine receptor common subunit gammatarget
Denileukin diftitoxInterleukin-2 receptor subunit betatarget
Peginterferon alfa-2aInterferon alpha/beta receptor 2target
Peginterferon alfa-2aInterferon alpha/beta receptor 1target
Peginterferon alfa-2aCytochrome P450 1A2enzyme
Interferon alfa-n1Interferon alpha/beta receptor 2target
Interferon alfa-n1Interferon alpha/beta receptor 1target
Interferon alfa-n1Cytochrome P450 1A2enzyme
Darbepoetin alfaErythropoietin receptortarget
ErythropoietinErythropoietin receptortarget
Interferon alfa-n3Interferon alpha/beta receptor 1target
Interferon alfa-n3Interferon alpha/beta receptor 2target
Interferon alfa-n3Cytochrome P450 1A2enzyme
PegfilgrastimGranulocyte colony-stimulating factor receptortarget
PegfilgrastimNeutrophil elastaseenzyme
SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
SargramostimBone marrow proteoglycantarget
SargramostimInterleukin-3 receptor subunit alphatarget
SargramostimCytokine receptor common subunit betatarget
SargramostimSyndecan-2target
Peginterferon alfa-2bInterferon alpha/beta receptor 1target
Peginterferon alfa-2bInterferon alpha/beta receptor 2target
Peginterferon alfa-2bCytochrome P450 1A2enzyme
Peginterferon alfa-2bCytochrome P450 2D6enzyme
Peginterferon alfa-2bCytochrome P450 2C9enzyme
AnakinraInterleukin-1 receptor type 1target
Interferon gamma-1bInterferon gamma receptor 1target
Interferon gamma-1bInterferon gamma receptor 2target
Interferon gamma-1bCytochrome P450 1A2enzyme
OprelvekinInterleukin-11 receptor subunit alphatarget
PaliferminFibroblast growth factor receptor 2target
PaliferminNeuropilin-1target
PaliferminFibroblast growth factor receptor 1target
PaliferminFibroblast growth factor receptor 4target
PaliferminFibroblast growth factor receptor 3target
PaliferminBasement membrane-specific heparan sulfate proteoglycan core proteintarget
AldesleukinInterleukin-2 receptor subunit betatarget
AldesleukinInterleukin-2 receptor subunit alphatarget
AldesleukinCytokine receptor common subunit gammatarget
AldesleukinProstaglandin G/H synthase 2enzyme
AldesleukinCytosolic phospholipase A2enzyme
AldesleukinCytochrome P450 3A4enzyme
AldesleukinXanthine dehydrogenase/oxidaseenzyme
AldesleukinCytochrome P450 2E1enzyme
Interferon beta-1aInterferon alpha/beta receptor 1target
Interferon beta-1aInterferon alpha/beta receptor 2target
Interferon beta-1aCytochrome P450 1A2enzyme
Interferon beta-1bInterferon alpha/beta receptor 1target
Interferon beta-1bInterferon alpha/beta receptor 2target
Interferon beta-1bCytochrome P450 1A2enzyme
Interferon alfacon-1Interferon alpha/beta receptor 1target
Interferon alfacon-1Interferon alpha/beta receptor 2target
Interferon alfacon-1Cytochrome P450 1A2enzyme
BecaplerminPlatelet-derived growth factor receptor betatarget
BecaplerminAlpha-2-macroglobulintarget
BecaplerminPlatelet-derived growth factor receptor alphatarget
MecaserminInsulin-like growth factor 1 receptortarget
MecaserminInsulin-like growth factor-binding protein 3target
MecaserminInsulin receptortarget
MecaserminCation-independent mannose-6-phosphate receptortarget
MecaserminInsulin-like growth factor-binding protein 3carrier
MecaserminInsulin-like growth factor-binding protein complex acid labile subunitcarrier
MecaserminInsulin-like growth factor-binding protein 1carrier
MecaserminInsulin-like growth factor-binding protein 2carrier
MecaserminInsulin-like growth factor-binding protein 4carrier
MecaserminInsulin-like growth factor-binding protein 5carrier
MecaserminInsulin-like growth factor-binding protein 6carrier
AbaloparatideParathyroid hormone/parathyroid hormone-related peptide receptortarget
LeptinLeptin receptortarget
Interferon alfaInterferon alpha/beta receptor 1target
Interferon alfaCytochrome P450 1A2enzyme
Cintredekin BesudotoxInterleukin-13target
RomiplostimThrombopoietin receptortarget
Albinterferon Alfa-2BCytochrome P450 1A2enzyme
CTCE-0214Stromal cell-derived factor 1target
IRL-1620Endothelin B receptortarget
IcatibantB2 bradykinin receptortarget
IcatibantAminopeptidase Ntarget
Endostatin72 kDa type IV collagenasetarget
EndostatinMatrix metalloproteinase-9target
EndostatinCollagenase 3target
EndostatinFocal adhesion kinase 1target
EndostatinE-selectintarget
EndostatinCytochrome P450 19A1enzyme
ThrombopoietinThrombopoietin receptortarget
LabradimilB2 bradykinin receptortarget
MetreleptinLeptin receptortarget
AncestimMast/stem cell growth factor receptor Kittarget
Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
Peginterferon beta-1aCytochrome P450 1A2enzyme
Dibotermin alfaBone morphogenetic protein receptor type-1Atarget
Dibotermin alfaBone morphogenetic protein receptor type-2target
LenograstimGranulocyte colony-stimulating factor receptortarget
LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
RegramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
RegramostimGM-CSF receptor alpha subunittarget
RegramostimCholinesteraseenzyme
Sar9, Met (O2)11-Substance PCytochrome P450 19A1enzyme
Sar9, Met (O2)11-Substance PCholinesteraseenzyme
Sar9, Met (O2)11-Substance PProstaglandin G/H synthase 2enzyme
Human interferon betaCytochrome P450 1A2enzyme
Human interferon betaInterferon alpha/beta receptor 1target
Human interferon betaSerum albumincarrier
Interferon alfa-2cCytochrome P450 1A2enzyme